Clinical trial
A Study to Evaluate the Tolerability, Safety and Effectiveness of Edratide in…
NCT00203151 · Teva Branded Pharmaceutical Products R&D, Inc., Industry · Terminated
Key facts
| NCT number | NCT00203151 |
|---|---|
| Title | A Study to Evaluate the Tolerability, Safety and Effectiveness of Edratide in the Treatment of Lupus |
| Official title | A Multi-National, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Multiple-Dose, Parallel Group Study to Assess the Efficacy, Tolerability and Safety of Edratide for Subcutaneous Injection in Systemic Lupus Erythematosus (SLE) |
| Acronym | PRELUDE |
| Lead sponsor | Teva Branded Pharmaceutical Products R&D, Inc., Industry |
| Status | Terminated |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Systemic Lupus Erythematosus |
| Intervention type | Drug |
| Interventions | edratide |
| Enrollment | 340 |
| Start date | Jul 1, 2005 |
| Primary completion | Feb 1, 2007 |
| Completion | Feb 1, 2007 |
| First posted | Sep 20, 2005 |
| Last update posted | Apr 12, 2011 |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: